{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:57:57Z","timestamp":1792936677377,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,28]]},"DOI":"10.7759\/cureus.29718","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T03:30:00Z","timestamp":1664422200000},"source":"Crossref","is-referenced-by-count":5,"title":["Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease"],"prefix":"10.7759","author":[{"given":"Brendan","family":"Andres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Taleban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn WJ","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao LL, et al.. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012, 367:1519-28. 10.1056\/NEJMoa1203572","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan BG","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al.. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016, 375:1946-60. 10.1056\/NEJMoa1602773","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease","volume":"14","author":"Hanauer SB","year":"2020","unstructured":"Hanauer SB, Sandborn WJ, Feagan BG, et al.. IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease. J Crohns Colitis. 2020, 14:23-32. 10.1093\/ecco-jcc\/jjz110","journal-title":"J Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.011","article-title":"Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials","volume":"66","author":"Lebwohl M","year":"2012","unstructured":"Lebwohl M, Leonardi C, Griffiths CE, et al.. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012, 66:731-41. 10.1016\/j.jaad.2011.06.011","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2015.06.003","article-title":"Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy","volume":"64","author":"Lis-\u015awi\u0119ty A","year":"2015","unstructured":"Lis-\u015awi\u0119ty A, Skrzypek-Salamon A, Arasiewicz H, Brzezi\u0144ska-Wcis\u0142o L. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy. Allergol Int. 2015, 64:382-3. 10.1016\/j.alit.2015.06.003","journal-title":"Allergol Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14295","article-title":"Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases","volume":"45","author":"Ishiuji Y","year":"2018","unstructured":"Ishiuji Y, Umezawa Y, Asahina A, Fukuta H, Aizawa N, Yanaba K, Nakagawa H. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases. J Dermatol. 2018, 45:732-4. 10.1111\/1346-8138.14295","journal-title":"J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12495","article-title":"Pathogenesis of atopic dermatitis","volume":"45","author":"Peng W","year":"2015","unstructured":"Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy. 2015, 45:566-74. 10.1111\/cea.12495","journal-title":"Clin Exp Allergy"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.021","article-title":"Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis","volume":"137","author":"Song H","year":"2016","unstructured":"Song H, Yoo Y, Hwang J, Na YC, Kim HS. Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol. 2016, 137:852-60. 10.1016\/j.jaci.2015.08.021","journal-title":"J Allergy Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02120-17","article-title":"Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn's disease patients","volume":"9","author":"Doherty MK","year":"2018","unstructured":"Doherty MK, Ding T, Koumpouras C, et al.. Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn's disease patients. mBio. 2018, 9:e02120-17. 10.1128\/mBio.02120-17","journal-title":"mBio"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's Disease","volume":"154","author":"Adedokun OJ","year":"2018","unstructured":"Adedokun OJ, Xu Z, Gasink C, et al.. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's Disease. Gastroenterology. 2018, 154:1660-71. 10.1053\/j.gastro.2018.01.043","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02271-4","article-title":"Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease","volume":"22","author":"Hirayama H","year":"2022","unstructured":"Hirayama H, Morita Y, Imai T, et al.. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease. BMC Gastroenterol. 2022, 22:195. 10.1186\/s12876-022-02271-4","journal-title":"BMC Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease","volume":"15","author":"Battat R","year":"2017","unstructured":"Battat R, Kopylov U, Bessissow T, et al.. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2017, 15:1427-34. 10.1016\/j.cgh.2017.03.032","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.02.035","article-title":"Effectiveness of ustekinumab dose escalation in patients with Crohn's disease","volume":"19","author":"Ollech JE","year":"2021","unstructured":"Ollech JE, Normatov I, Peleg N, et al.. Effectiveness of ustekinumab dose escalation in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2021, 19:104-10. 10.1016\/j.cgh.2020.02.035","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15784","article-title":"Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy","volume":"52","author":"Kopylov U","year":"2020","unstructured":"Kopylov U, Hanzel J, Liefferinckx C, et al.. Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Aliment Pharmacol Ther. 2020, 52:135-42. 10.1111\/apt.15784","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa282","article-title":"Predictors of ustekinumab failure in Crohn's disease after dose intensification","volume":"27","author":"Dalal RS","year":"2021","unstructured":"Dalal RS, Njie C, Marcus J, Gupta S, Allegretti JR. Predictors of ustekinumab failure in Crohn's disease after dose intensification. Inflamm Bowel Dis. 2021, 27:1294-301. 10.1093\/ibd\/izaa282","journal-title":"Inflamm Bowel Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa177","article-title":"Effectiveness and safety of ustekinumab intensification at 90 mg every four weeks in Crohn's disease: a multicenter study","volume":"15","author":"Fumery M","year":"2020","unstructured":"Fumery M, Peyrin-Biroulet L, Nancey S, et al.. Effectiveness and safety of ustekinumab intensification at 90 mg every four weeks in Crohn's disease: a multicenter study. J Crohns Colitis. 2020, 15:222-7. 10.1093\/ecco-jcc\/jjaa177","journal-title":"J Crohns Colitis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820959245","article-title":"Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease","volume":"13","author":"Haider SA","year":"2020","unstructured":"Haider SA, Yadav A, Perry C, et al.. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease. Therap Adv Gastroenterol. 2020, 13:1-9. 10.1177\/1756284820959245","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/93411-exacerbation-of-atopic-dermatitis-associated-with-ustekinumab-treatment-in-crohns-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:25Z","timestamp":1707507625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/93411-exacerbation-of-atopic-dermatitis-associated-with-ustekinumab-treatment-in-crohns-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.29718","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}